Yearly Archives: 2018


Amorsa Therapeutics Appoints Jeffrey Wiesen to Board of Directors

Southborough, MA, June 1, 2018 – Amorsa Therapeutics Inc., a neuropharmaceutical company pioneering the development of breakthrough treatments for nervous system disorders, is pleased to announce the appointment of Jeffrey Wiesen to its Board of Directors. As the former Chair of Mintz Levin’s Life Sciences Practice, Jeff has been a leader in the biotechnology industry since its inception and has actively assisted numerous companies ranging from newly formed start-up ventures to public pharmaceutical companies. “We are thrilled to welcome Jeff to our Board,” said Joe Blanchard, President and Chief Executive Officer of Amorsa. “Jeff is an industry veteran and has More


Amorsa Therapeutics Announces Notice of Allowance for U.S. Patent Covering Oral Compositions of Ketamine and Related Compounds

Southborough, MA, January 9, 2018 – Amorsa Therapeutics, Inc., a neuropharmaceutical company pioneering the development of breakthrough treatments for nervous system disorders, announced today that its patent application for oral compositions of ketamine and related compounds was allowed for issuance as a new patent by the U.S. Patent and Trademark Office (USPTO). The U.S. patent will not expire until after 2033. “This new patent directed toward Amorsa’s anticipated commercial formulations marks another significant accomplishment for the company,” said Dr. Alex Nivorozhkin, COO of Amorsa and co-inventor on this patent. “There’s tremendous commercial potential for Amorsa’s technology to treat several nervous More